Abstracts tagged "Abatacept"

Abstract Number: 1683 • ACR Convergence 2021
Abatacept in Usual and in Non-Specific Interstitial Pneumonia Associated to Rheumatoid Arthritis. National Multicenter Study of 190 Patients
Belén Atienza-Mateo¹, Carlos Fernández-Díaz², Santos Castañeda³, Rafael Melero⁴, Francisco Ortiz-Sanjuán⁵, Ivette Casafont⁶, Sebastián C. Rodríguez-García⁷, Iván Ferraz-Amaro⁸, Miguel Ángel gonzalez-Gay⁹ and Ricardo Blanco¹⁰, ¹Group "Research in genetic epidemiology and atherosclerosis of systemic diseases and in bone metabolic diseases of the locomotor system", IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Universitario Reina Sofía, Murcia, Spain, ³Hospital Universitario de la Princesa, Madrid, Spain, ⁴Complexo Hospitalario Universitario de Vigo, Vigo, Galicia, Spain, ⁵Hospital Universitario La Fe, Valencia, Spain, ⁶Hospital Universitari Germans Trias i Pujol, Barcelona, Badalona, Spain, ⁷Hospital Universitario Clinic, Barcelona, Spain, ⁸Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁹Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ¹⁰Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Interstitial lung disease (ILD) is a severe complication of Rheumatoid Arthritis (RA). Usual interstitial pneumonia (UIP) is considered to be more frequent and severe…
Abstract Number: 0322 • ACR Convergence 2021
Histopathological Changes in Parotid and Labial Salivary Gland Tissue in Primary Sjögren’s Syndrome Patients After Abatacept Treatment
Uzma Nakshbandi¹, Liseth de Wolff², Frans Kroese¹, Silvia Liefers³, Neelanjana Ray⁴, Gwenny Verstappen¹, Fred Spijkervet³, Marleen Nys⁵, Arjan Vissink⁶, Robert Wong⁷, Bert van der vegt³ and Hendrika Bootsma¹, ¹University Medical Center Groningen, Groningen, Netherlands, ²University Medical Centre Groningen, Groningen, Netherlands, ³University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁴Bristol-Myers Squibb Company, Lawrenceville, GA, ⁵Bristol Myers Squibb, Braine-l'Alleud, Belgium, ⁶University of Groningen, University Medical Center Groningen, Leek, Netherlands, ⁷Bristol Myers Squibb, Basking Ridge, NJ
Background/Purpose: In a previous open-label phase II study, we showed that abatacept treatment might inhibit local formation of autoreactive memory B cells in parotid glands…
Abstract Number: 1242 • ACR Convergence 2021
Sex Differences in Treatment Response to Three Different Biological Treatments and Corticosteroids in Patients with Early Rheumatoid Arthritis
Kristina Lend¹, Ronald F van Vollenhoven², Jon Lampa³, Merete Hetland⁴, Espen Haavardsholm⁵, Dan Nordström⁶, Michael Nurmohamed⁷, Bjorn Gudbjornsson⁸, Anna Rudin⁹, Mikkel Ostergaard¹⁰, Till Uhlig¹¹, Gerdur Grondal⁸, Kim Hørslev-Petersen¹², Marte S Heiberg⁵, Tuulikki Sokka-Isler¹³, Jos Twisk¹⁴ and Irene van der Horst-Bruinsma¹⁵, ¹Department of Medicine, Rheumatology Unit, The Karolinska Institute, Stockholm, Sweden, ²Amsterdam University Medical Centers, Department of Rheumatology and Clinical Immunology, Rheumatology and Immunology Center ARC, Amsterdam, Netherlands, ³Karolinska University Hospital, Department of Medicine, Rheumatology Unit, The Karolinska Institute, Stockholm, Sweden, Stockholm, Sweden, ⁴DANBIO and COPECARE, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, ⁵Diakonhjemmet Hospital, Oslo, Norway, ⁶Division of Internal Medicine and Rheumatology, Helsinki University Hospital, Helsinki, Finland, ⁷Amsterdam University Medical Centers, Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ⁸Landspitali University Hospital, University of Iceland, Reykjavik, Iceland, ⁹Rheumatology Clinic, Sahlgrenska University Hospital, Sahlgrenska Academy of University of Gothenburg, Gothenburg, Sweden, ¹⁰Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, and Department of Clinical Medicine, University of Copenhagen, Glostrup, Denmark, ¹¹Diakonhjemmet Hospital, University of Oslo, Oslo, Norway, ¹²Danish Hospital for Rheumatic Diseases, University of Southern Denmark, Reykjavik, Iceland, Haderslev, Denmark, ¹³University of Eastern Finland, Jyväskylä Central Hospital, Jyväskylä, Finland, ¹⁴Department of Epidemiology and Biostatistics, Amsterdam University Medical Centres, Amsterdam, Netherlands, ¹⁵Department of Rheumatology, VU University Medical Centre, Amsterdam, Netherlands
Background/Purpose: To investigate sex differences in clinical response to three different biological treatments in combination with methotrexate (MTX) versus MTX plus corticosteroids (active conventional treatment;…
Abstract Number: 024 • 2020 Pediatric Rheumatology Symposium
Abatacept Treatment Reduces Cutaneous and Joint Activity in Juvenile Localized Scleroderma
Suzanne Li¹, Sarah Ishaq ², Mary Buckley ³, Kathryn Torok ⁴, Barbara Edelheit ⁵, Kaleo Ede ⁶ and C. Egla Rabinovich ⁷, ¹Joseph M. Sanzari Children's Hospital Hackensack Meridian Health, Hackensack, ²Montclair State University, montclair, ³Duke University, Durham, ⁴Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh, ⁵CT Children's Medical Center, Hartford, ⁶Phoenix Children's Hospital, Phoenix, ⁷Duke University Hospital, Durham
Background/Purpose: Juvenile localized scleroderma (jLS) is an autoimmune disease commonly associated with damage. Damage includes dyspigmentation, tissue atrophy, arthropathy, hemiatrophy, vision loss, and seizures. To…
Abstract Number: L09 • 2019 ACR/ARP Annual Meeting
A Multicenter Randomized Study in Early Rheumatoid Arthritis to Compare Active Conventional Therapy versus Three Biological Treatments: 24 Week Efficacy and Safety Results of the NORD-STAR Trial
Merete Lund Hetland¹, Espen A Haavardsholm ², Anna Rudin ³, Dan Nordström ⁴, Mike Nurmohamed ⁵, Bjorn Gudbjornsson ⁶, Jon Lampa ⁷, Kim Hørslev-Petersen ⁸, Till Uhlig ⁹, Gerdur Grondal ¹⁰, Mikkel Østergaard ¹¹, Marte Heiberg ², Jos Twisk ¹², Kristina Lend ⁷, Simon Krabbe ¹³, Joakim Lindqvist ⁷, Anna-Karin Ekwall ¹⁴, Kathrine Lederballe Grøn ¹⁵, Meliha Kapetanovic ¹⁶, Francesca Faustini ⁷, Riitta Tuompo ¹⁷, Tove Lorenzen ¹⁸, Giovanni Cagnotto ¹⁹, Eva Baecklund ²⁰, Oliver Hendricks ²¹, Daisy Vedder ²², Tuulikki Sokka-isler ²³, Tomas Husmark ²⁴, Maud-Kristine Aga Ljoså ²⁵, Eli Brodin ²⁶, Torkell Ellingsen ²⁷, Annika Söderbergh ²⁸, Milad Rizk ²⁹, Åsa Reckner ³⁰, Line Uhrenholt ³¹, Per Larsson ³², Soeren Just ³³, David Stevens ³⁴, Trine Laurberg ³⁵, Gunnstein Bakland ³⁶, Inge Christoffer Olsen ³⁷, Ronald van Vollenhoven ³⁸ and The NORD-STAR Study Group ³⁹, ¹DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark, ²Diakonhjemmet Hospital, Oslo, Norway, ³Dept Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Göteborg, Sweden, ⁴Department of Medicine, ROB-FIN, Helsinki University Hospital and Helsinki University, Helsinki, Finland., Helsinki, Finland, ⁵Amsterdam Rheumatology and immunology Center location Reade and Amsterdam UMC location VU medical center, Amsterdam, Netherlands, ⁶Centre for Rheumatology Research, Landspitali and Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ⁷Karolinska Institutet, Stockholm, Sweden, ⁸Department of Rheumatology, King Christian X's Hospital for Rheumatic Diseases Graasten, Denmark, Graasten, Denmark, ⁹Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, ¹⁰Department of Rheumatology, Landspitali and Centre for Rheumatology Research, Landspitali, Reykjavík, Iceland, ¹¹Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark, ¹²Department of Epidemiology and Biostatistics, Amsterdam UMC, Amsterdam, Netherlands, ¹³Rigshospitalet, København, Denmark, ¹⁴University of Gothenburg, Kullavik, Sweden, ¹⁵Rigshospitalt Glostrup, Glostrup, Denmark, ¹⁶Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Section of Rheumatology, Lund and Malmö, Sweden, Lund, Sweden, ¹⁷Helsinki University Hospital, Helsinki, Finland, ¹⁸Reumatologi, Regionshospitalet Silkeborg, Kolding, Denmark, ¹⁹Lund University, Malmö, Sweden, ²⁰Uppsala University, Uppsala, Sweden, ²¹Danish Hospital for Rheumatic Diseases, Sønderborg, Denmark, ²²Amsterdam Rheumatology & immunology Center / Reade, Amsterdam, Netherlands, ²³Jyvaskyla Central Hospital, Jyvaskyla, Finland, ²⁴Rheumatology Clinic, Falun, Sweden, ²⁵Ålesund Hospital Helse Møre og Romsdal HF, Ålesund, Norway, ²⁶Haukeland University Hospital, Bergen, Norway, ²⁷Department of Rheumatology, Odense University Hospital, Denmark, Odense, Syddanmark, Denmark, ²⁸Örebro University Hospital, Ôrebro, Sweden, ²⁹Västmanlands Hospital, Västerås, Sweden, ³⁰Rheumatology Department, Linkoping, Sweden, ³¹Aalborg Universitetshospital, Aalborg, Denmark, ³²Center for Rheumatology, Academic Specialist Center, Stockholm Health Services, Stockholm, Sweden, Stockholm, Stockholms Lan, Sweden, ³³Odense University Hospital, Odense, ³⁴St. Olav's University Hospital, Trondheim, Norway, ³⁵Aarhus University Hospital, Aarhus, Denmark, ³⁶University Hospital of North Norway, Tromsø, Norway, ³⁷Oslo University Hospital, Oslo, Norway, ³⁸Amsterdam Rheumatology and immunology Center, Netherlands., Amsterdam, Netherlands, ³⁹Site investigators in all participating countries, Stockholm, Sweden
Background/Purpose: The optimal first-line treatment of patients (pts) with early rheumatoid arthritis (RA) is yet to be established. The primary aim was to assess and…
Abstract Number: L11 • 2019 ACR/ARP Annual Meeting
Maintenance of Remission Following Dose De-Escalation of Abatacept in Early, MTX-Naïve, ACPA-Positive Patients with RA: Results from a Randomized Phase IIIb Study
Paul Emery¹, Yoshiya Tanaka ², Vivian Bykerk ³, Thomas W.J. Huizinga ⁴, Gustavo Citera ⁵, Clifton Bingham ⁶, Subhashis Banerjee ⁷, Benjamin Soule ⁸, Marleen Nys ⁹, Sean Connolly ¹⁰, Robert Wong ¹⁰, Kuan-Hsiang Gary Huang ⁷ and Roy Fleischmann ¹¹, ¹University of Leeds and Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ²University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ³Hospital for Special Surgery, New York City, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, ⁶Johns Hopkins University, Baltimore, ⁷Bristol-Myers Squibb, Princeton, NJ, ⁸Bristol-Myers Squibb, Princeton, New Jersey, ⁹Bristol-Myers Squibb, Braine L'Alleud, Belgium, ¹⁰Bristol-Myers Squibb, Princeton, ¹¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Although EULAR/ACR guidelines suggest tapering biologics following sustained remission in patients (pts) with RA, specific de-escalation (DE) regimens are not fully defined. The Phase…
Abstract Number: 1425 • 2019 ACR/ARP Annual Meeting
Effect of ACPA IgM Serostatus on Efficacy Outcomes Following Treatment with Abatacept or Adalimumab: A Post Hoc Analysis of a Phase III Head-to-Head Trial
Thomas Huizinga¹, René Toes ¹, Michael Weinblatt ², Michael Schiff ³, Roy Fleischmann ⁴, Yedid Elbez ⁵, Sean Connolly ⁶, Michael Maldonado ⁶ and Sheng Gao ⁶, ¹Leiden University Medical Center, Leiden, Netherlands, ²Brigham and Women's Hospital, Boston, MA, USA, Boston, MA, ³University of Colorado, Denver, CO, ⁴Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ⁵Excelya, Boulogne-Billancourt, France, ⁶Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: Anti-citrullinated protein antibody (ACPA) is a marker for early, erosive RA.1 In the Abatacept (ABA) versus adaliMumab (ADA) comParison in bioLogic-naïvE RA subjects with…
Abstract Number: 1429 • 2019 ACR/ARP Annual Meeting
Results at 6 Months of Abatacept vs TNF-α Blockers in Patients with Severe, Long-standing, DMARDs Resistant Rheumatoid Arthritis
Omar Valenzuela ¹, Sebastian Ibanez², Maria Paz Poblete ³, Claudia Mardones ², Francisco Silva ², Maria Jose Villar ² and Katherine Mogollones ¹, ¹Facultad de Medicina Clinica Alemana -UDD, Santiago, Region Metropolitana, Chile, ²Facultad de Medicina Clinica Alemana - UDD, Santiago, Region Metropolitana, Chile, ³Rheumatology dpt., Facultad de Medicina Clinica Alemana - UDD, Santiago, Region Metropolitana, Chile
Background/Purpose: Since January 2016, Chilean patients with rheumatoid arthritis (RA), with severe activity despite the use of 3 DMARDs for at least 6 months, have guaranteed access…
Abstract Number: 1437 • 2019 ACR/ARP Annual Meeting
Comparison of the Efficacy and Safety of Abatacept in Rheumatoid Arthritis Patients with and Without Interstitial Lung Disease
Sho Sasaki¹, Akira Ishii ², Mai Sugiyama ², Yuto Izumi ², Yoko Nakagome ², Kazuki Hirano ³, Takayoshi Kurabayashi ¹, Noriko Sasaki ², Chiho Yamada ² and Shinji Sato ⁴, ¹Tokai Universitiy School of Medicine, Isehara, Japan, ²Tokai University School of Medicine, Isehara, Japan, ³Tokai University School of Medicine, Isehara, ⁴Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Yokohama, Japan
Background/Purpose: Interstitial lung disease (ILD) is one of complication in patients with rheumatoid arthritis (RA) and its presence often has an effect on the management…
Abstract Number: 1442 • 2019 ACR/ARP Annual Meeting
Comparison of Sustained Clinical Remission And/or Low Disease Activity Rate Between Rapidly and Gradually De-escalation of Abatacept in Rheumatoid Arthritis
MASAOMI YAMASAKI¹, ¹Shin-Yokohama Arthritis and Rheumatology Clinic, Yokohama, Japan
Background/Purpose: However biological DMARDs (bDMARDs) and treatment strategies have improved the outcomes of rheumatoid arthritis (RA), it is unknown who can taper or stop bDMARDs…
Abstract Number: 1815 • 2019 ACR/ARP Annual Meeting
Subcutaneous or Intravenous Abatacept Monotherapy in Pediatric Patients with Polyarticular-Course JIA: Results from Two Phase III Trials
Nicolino Ruperto¹, Daniel J. Lovell ², John Bohnsack ³, Johannes Breedt ⁴, Michel Fischbach ⁵, Thomas Lutz ⁶, Kirsten Minden ⁷, Tatiana Miraval ⁸, Mahmood M. T. M. Ally ⁹, Nadina Rubio-Pérez ¹⁰, Elisabeth Gervais ¹¹, Riana van Zyl ¹², Robert Wong ¹³, Marleen Nys ¹⁴, Alberto Martini ¹⁵ and Hermine Brunner ¹⁶, ¹Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, ²Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, ³University of Utah School of Medicine, Salt Lake City, UT, ⁴Steve Biko Academic Hospital, University of Pretoria, Pretoria, South Africa, ⁵Pédiatrie 1, CHU Hautepierre, Strasbourg, France, ⁶Heidelberg University Hospital, Heidelberg, Germany, ⁷German Rheumatism Research Center and Charité University Medicine, Berlin, Germany, ⁸Clínica San Gabriel, Lima, Peru, ⁹University of Pretoria, Pretoria, South Africa, ¹⁰University Hospital Dr. José Eleuterio González, Monterrey, Mexico, ¹¹CHU de Poitiers, Rheumatology, Poitiers, France, ¹²University of the Free State, Bloemfontein, South Africa, ¹³Bristol-Myers Squibb, Princeton, ¹⁴Bristol-Myers Squibb, Braine L’Alleud, Belgium, ¹⁵IRCCS Istituto Giannina Gaslini, Università degli Studi di Genova, Genova, Italy, ¹⁶Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
Background/Purpose: In EU, abatacept (ABA) with MTX is approved in patients (pts) with polyarticular-course JIA (pJIA), as young as 2 years (SC) and 6 years…
Abstract Number: 1928 • 2019 ACR/ARP Annual Meeting
Identification of Immunological Processes Associated with the Response to Abatacept in Rheumatoid Arthritis Using Longitudinal Blood RNA-seq Analysis
Antonio Julià¹, Maria Lopez Lasanta ², Antonio Gómez ³, Irene Bonafonte ⁴, Raimon Sanmartí ⁵, Carlos Marras ⁶, José Manuel Pina ⁷, Susana Romero-Yuste ⁸, Raul Veiga ⁹, Pilar Navarro ⁹, Carmen Moragues Pastor ¹⁰, Silvia Martínez ¹¹, Francisco J. De Toro ¹², Amalia Sanchez ¹³, Dacia Cerdà ¹⁴, Alejandro Prada ¹⁵, Alba Erra ¹⁶, Jordi Monfort ¹⁷, A. Urruticoechea-Arana ¹⁸, Núria Palau ¹⁹, Raquel Lastra ²⁰, Raúl Tortosa ³, Andrea Pluma ²¹ and Sara Marsal ²², ¹Rheumatology Research Group, Vall d’Hebron Hospital Research Institute, Barcelona, Spain., Barcelona, Catalonia, Spain, ²Hospital Universitari Vall Hebrón, Barcelona, Barcelona, Catalonia, Spain, ³Hospital Vall d'Hebron, Barcelona, Barcelona, Spain, ⁴Vall Hebron Hospital Research Institute, Barcelona, Spain, ⁵Hospital Clínic, Barcelona, Barcelona, Spain, ⁶Hospital Universitario Virgen de la Arrixaca, Murcia, Murcia, Spain, ⁷Hospital de Barbastro, Huesca, Barbastro, Huesca, Spain, ⁸Complejo Hospitalario Universitario Pontevedra, Pontevedra, Galicia, Spain, ⁹Hospital Universitario Fuenlabrada, Fuenlabrada, Spain, ¹⁰Platò Hospital, Barcelona, Spain, Barcelona, Spain, ¹¹Hospital Universitari Mútua Terrassa, Terrassa, Spain, ¹²University Hospital A Coruña, A Coruña, Spain, ¹³Hospital Universitario Lucus Augusti, Lugo, Lugo, Spain, ¹⁴Hospital Moisès Broggi, Sant Joan Despí, Sant Joan Despí, Spain, ¹⁵Hospital Universitario Torrejón de Ardoz, Torrejón de Ardoz, Spain, ¹⁶Hospital Sant Rafael, Barcelona, Barcelona, Spain, ¹⁷Hospital del Mar, Barcelona, Spain, ¹⁸HU Can Misses, Ibiza, Spain, ¹⁹Hospital Vall Hebrón Barcelona, Barcelona, Spain, ²⁰Hospital Vall Hebron, Barcelona, Barcelona, Spain, ²¹Hospital Universitari Vall d'Hebron, Barcelona, Spain, ²²Vall d’Hebron Hospital, Barcelona, Catalonia, Spain
Background/Purpose: Abatacept (CTLA4-Ig) is an approved biological therapy for the treatment of rheumatoid arthritis (RA). Similar to other biological agents, most patients (50-60%) respond significantly…
Abstract Number: 2381 • 2019 ACR/ARP Annual Meeting
Baseline Characteristics Associated with Sustained SDAI Remission Following Treatment with Abatacept in Combination with MTX Compared with Abatacept Placebo in Combination with MTX in ACPA Positive Patients with Early RA
Paul Emery¹, Yoshiya Tanaka ², Vivian Bykerk ³, Clifton Bingham ⁴, Thomas Huizinga ⁵, Gustavo Citera ⁶, Kuan-Hsiang Gary Huang ⁷, Sean Connolly ⁷, Yedid Elbez ⁸, Karissa Lozenski ⁹ and Roy Fleischmann ¹⁰, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ²University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ³Hospital for Special Surgery, New York City, NY, ⁴Johns Hopkins University, Baltimore, MD, ⁵Leiden University Medical Center, Leiden, Netherlands, ⁶Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, ⁷Bristol-Myers Squibb, Princeton, NJ, ⁸Excelya, Boulogne-Billancourt, France, ⁹Bristol-Myers Squibb, Princeton, ¹⁰Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: The Phase IIIb Assessing Very Early Rheumatoid arthritis Treatment (AVERT)-2 trial (NCT02504268) is evaluating SC abatacept (ABA) + MTX versus ABA placebo (PBO) +…
Abstract Number: 2707 • 2019 ACR/ARP Annual Meeting
Improvement in Patient-Reported Outcomes in Patients Aged 2–5 Years with Polyarticular-Course JIA Treated with Subcutaneous Abatacept: 2-Year Results from a Phase III International Study
Hermine Brunner¹, Nikolay Tzaribachev ², Ingrid Louw ³, Jordi Antón ⁴, Diego Viola ⁵, Bernard Lauwerys ⁶, Rubèn J Cuttica ⁷, Pierre Quartier ⁸, Elisabeth Gervais ⁹, Alexandre Belot ¹⁰, Kirsten Minden ¹¹, Thomas Lutz ¹², Rolando Cimaz ¹³, Mahmood M. T. M. Ally ¹⁴, Riana van Zyl ¹⁵, Inmaculada Calvo Penadés ¹⁶, Joe Zhuo ¹⁷, Robert Wong ¹⁸, Marleen Nys ¹⁹, Yedid Elbez ²⁰, Alberto Martini ²¹, Daniel J. Lovell ²² and Nicolino Ruperto ²³, ¹Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Pediatric Rheumatology Research Institute, Bad Bramstedt, Germany, ³Panorama Medical Centre, Parow, South Africa, ⁴Hospital Sant Joan de Déu, Barcelona, Spain, ⁵CAICI Institute, Rosario City, Santa Fe State, Argentina, ⁶Rheumatology, Cliniques universitaires Saint-Luc - Université Catholique de Louvain - Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, Brussels, Belgium, ⁷Hospital General de Niños Pedro de Elizalde, Buenos Aires, Argentina, ⁸Necker Hospital, Paris, France, ⁹CHU de Poitiers, Rheumatology, Poitiers, France, ¹⁰Centre Hospitalier Universitaire de Lyon, Lyon, France, ¹¹German Rheumatism Research Center and Charité University Medicine, Berlin, Germany, ¹²Heidelberg University Hospital, Heidelberg, Germany, ¹³Meyer Children's Hospital in Florence, Florence, Italy, ¹⁴University of Pretoria, Pretoria, South Africa, ¹⁵University of the Free State, Bloemfontein, South Africa, ¹⁶Hospital Univ. La Fe, Valencia, Spain, ¹⁷Bristol-Myers Squibb, Princeton, NJ, ¹⁸Bristol-Myers Squibb, Princeton, ¹⁹Bristol-Myers Squibb, Braine L’Alleud, Belgium, ²⁰Excelya, Boulogne-Billancourt, France, ²¹IRCCS Istituto Giannina Gaslini, Università degli Studi di Genova, Genova, Italy, ²²Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, ²³Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy
Background/Purpose: Efficacy of SC abatacept in patients with polyarticular-course JIA (pJIA) was shown in a 2-year, open-label, Phase III international study (NCT01844518).1 Pediatric patient-reported outcomes…
Abstract Number: 249 • 2019 ACR/ARP Annual Meeting
Evaluation of Real-World Early-Line Abatacept versus Tumor Necrosis Factor Inhibitors Persistence in Rheumatoid Arthritis Patients with Anti-Citrullinated Protein Antibody or Rheumatoid Factor Positivity
Damemarie Paul ¹, Xue Han², Irina Yermilov ³, Sarah Gibbs ³ and Michael Broder ³, ¹Bristol-Myers Squibb, Lawrenceville, NJ, ²Bristol-Myers Squibb Company, Princeton, NJ, ³Partnership for Health Analytic Research, LLC, Beverly Hills, CA
Background/Purpose: Abatacept is recommended as first-line biologic therapy in adult patients with moderate to severe RA. We aimed to assess real-world 1-year treatment persistence in…

1
2
3
…
12
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].